drugset / Trial / NCT00098124
Study of Milnacipran for the Treatment of Fibromyalgia
RandomizedParallel-groupDouble-blindTreatment
Summary
Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.
Timeline
- Start
- 2004-11
- Primary completion
- —
- Completion
- 2006-12
Outcome
Met primary endpoint
paper Compared with placebo, significantly greater proportions of milnacipran-treated patients were FM composite responders (100 mg/d: P = 0.01; 200 mg/d: P = 0.02) and FM pain composite responders (100 mg/d: P = 0.03; 200 mg/d: P = 0.004). PMID 19108787 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Milnacipran | Other / unclassified | 100 mg | — |
| Subject | Milnacipran | Other / unclassified | 200 mg | — |